Phenotypes associated with this allele
respiratory system
|
|
• 2 weeks after 5-hydroxytamoxifen treatment, lungs show increased cellularity
|
|
|
• lungs show multicellular septa and reduction of the alveolar lumen as early as 2 weeks after 5-hydroxytamoxifen treatment, and is marked after 8 weeks, extending to 60% of the lungs
|
|
|
• after 5-hydroxytamoxifen treatment, there is an increase in alveolar type II cells compared to controls
• when cultured, isolated progenitor and stem cells (SP-C+, CC-10+ cells) when put under differentiation conditions do not have the capacity to form single positive cells; overexpression of C/EBP alpha in these cells restores the capacity to form SP-C+ cells
|
cellular
|
|
• 8 weeks after 5-hydroxytamoxifen treatment, lungs display hyperproliferation (~5-fold increased proliferation) compared to wild-type or heterozygous lungs
|
reproductive system
|
|
• XY sex reversal of gonads at E14.5
|
Developmental defects in Mapk14tm2Nbr/Mapk14tm2Nbr Edil3Tg(Sox2-cre)1Amc/0 Mapk11tm1Jsca/Mapk11tm1Jsca embryos
mortality/aging
|
|
• all die between E16.5 and E18.5
|
nervous system
|
|
• spina bifida is correlated with neural hyperproliferation
|
|
|
• in 30% of mice at E13.5
|
cardiovascular system
|
|
• decreased proliferation at E13.5
|
liver/biliary system
|
|
• at E13.5 dissociated hepatocytes and infiltration of hematopoietic cells are seen
|
reproductive system
|
|
• complete XY sex reversal of gonads at E14.5
|
muscle
|
|
• decreased proliferation at E13.5
|
embryo
cellular
|
|
• decreased proliferation at E13.5
|
|
|
• spina bifida is correlated with neural hyperproliferation
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Edil3Tg(Sox2-cre)1Amc mutation
(5 available);
any
Edil3 mutation
(42 available)
Mapk11tm1Jsca mutation
(0 available);
any
Mapk11 mutation
(35 available)
Mapk14tm2Nbr mutation
(2 available);
any
Mapk14 mutation
(41 available)
Mapk14tm3.1(Mapk11)Nbr mutation
(0 available);
any
Mapk14 mutation
(41 available)
|
|
|
Cardiac defects in Mapk14tm3.1(Mapk11)Nbr/Mapk14tm2Nbr Edil3Tg(Sox2-cre)1Amc/0 Mapk11tm1Jsca/Mapk11tm1Jsca embryos
mortality/aging
|
|
• present in the expected numbers at E18.5 but none are found at weaning
|
cardiovascular system
nervous system
|
N |
• spina bifida phenotype seen in double null mice is rescued in mice carrying the Mapk14tm3.1(Mapk11)Nbr allele
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mapk14tm1Nbr mutation
(0 available);
any
Mapk14 mutation
(41 available)
Mapk14tm2Nbr mutation
(2 available);
any
Mapk14 mutation
(41 available)
Polr2atm1(cre/ERT2)Bbd mutation
(3 available);
any
Polr2a mutation
(92 available)
|
|
|
mortality/aging
|
|
• mice die before week 32 due to increased lung cancer progression
|
respiratory system
|
|
• 20 weeks after treatment, lungs are increased in size
|
|
|
• 2 weeks after 5-hydroxytamoxifen treatment, small tumors are found in the lungs
• 20 weeks after treatment, lungs are oversized with 2-3 times as many tumors, many often >2mm in diameter, while lungs of Kras, Mapk14 heterozygotes have normal lungs with fewer, smaller tumors; tumors in Mapk14 homozygotes are more poorly differentiated and have higher mitotic indices
• at 26 weeks, total tumor number is slightly higher than in controls with much higher numbers of tumors larger than 2 mm in diameter and a higher ratio of lung mass to total mass
|
|
|
• tumors are detected 2 weeks after 5-hydroxytamoxifen treatment and after 4 weeks, clear signs of adenomas are present in most lungs compared to only a few small adenomas in lungs of treated Kras, Mapk14tm2Nbr/+ control mice
|
|
|
• adenocarcinomas are detected at 15 weeks but not in controls
|
|
|
• lung differentiation is abnormal with increased SP-C-positive cells
|
neoplasm
|
|
• mice also have tumors in the thymus and organs such as kidney and liver by 24 weeks after treatment whereas controls only have tumors in lungs and thymus
|
|
|
• 2 weeks after 5-hydroxytamoxifen treatment, small tumors are found in the lungs
• 20 weeks after treatment, lungs are oversized with 2-3 times as many tumors, many often >2mm in diameter, while lungs of Kras, Mapk14 heterozygotes have normal lungs with fewer, smaller tumors; tumors in Mapk14 homozygotes are more poorly differentiated and have higher mitotic indices
• at 26 weeks, total tumor number is slightly higher than in controls with much higher numbers of tumors larger than 2 mm in diameter and a higher ratio of lung mass to total mass
|
|
|
• tumors are detected 2 weeks after 5-hydroxytamoxifen treatment and after 4 weeks, clear signs of adenomas are present in most lungs compared to only a few small adenomas in lungs of treated Kras, Mapk14tm2Nbr/+ control mice
|
|
|
• adenocarcinomas are detected at 15 weeks but not in controls
|
growth/size/body
|
|
• 20 weeks after treatment, lungs are increased in size
|
mortality/aging
|
|
• mice die before week 32 due to increased lung cancer progression
|
respiratory system
|
|
• 20 weeks after treatment, lungs are increased in size
|
|
|
• 2 weeks after 5-hydroxytamoxifen treatment, small tumors are found in the lungs
• 20 weeks after treatment, lungs are oversized with 2-3 times as many tumors, many often >2mm in diameter, while lungs of Kras, Mapk14 heterozygotes have normal lungs with fewer, smaller tumors; tumors in Mapk14 homozygotes are more poorly differentiated and have higher mitotic indices
• at 26 weeks, total tumor number is slightly higher than in controls with much higher numbers of tumors larger than 2 mm in diameter and a higher ratio of lung mass to total mass
|
|
|
• tumors are detected 2 weeks after 5-hydroxytamoxifen treatment and after 4 weeks, clear signs of adenomas are present in most lungs compared to only a few small adenomas in lungs of treated Kras, Mapk14tm2Nbr/+ control mice
|
|
|
• adenocarcinomas are detected at 15 weeks but not in controls
|
|
|
• lung differentiation is abnormal with increased SP-C-positive cells
|
neoplasm
|
|
• mice also have tumors in the thymus and organs such as kidney and liver by 24 weeks after treatment whereas controls only have tumors in lungs and thymus
|
|
|
• 2 weeks after 5-hydroxytamoxifen treatment, small tumors are found in the lungs
• 20 weeks after treatment, lungs are oversized with 2-3 times as many tumors, many often >2mm in diameter, while lungs of Kras, Mapk14 heterozygotes have normal lungs with fewer, smaller tumors; tumors in Mapk14 homozygotes are more poorly differentiated and have higher mitotic indices
• at 26 weeks, total tumor number is slightly higher than in controls with much higher numbers of tumors larger than 2 mm in diameter and a higher ratio of lung mass to total mass
|
|
|
• tumors are detected 2 weeks after 5-hydroxytamoxifen treatment and after 4 weeks, clear signs of adenomas are present in most lungs compared to only a few small adenomas in lungs of treated Kras, Mapk14tm2Nbr/+ control mice
|
|
|
• adenocarcinomas are detected at 15 weeks but not in controls
|
growth/size/body
|
|
• 20 weeks after treatment, lungs are increased in size
|
mortality/aging
|
|
• mice live up to 40 weeks
|
neoplasm
|
|
• by 24 weeks, mice develop tumors in the thymus
|
|
|
• by 24 weeks, mice develop tumors in lungs
|
|
|
• at 4 weeks after 5-hydroxytamoxifen treatment, a few small adenomas are observed in some animals
|
respiratory system
|
|
• by 24 weeks, mice develop tumors in lungs
|
|
|
• at 4 weeks after 5-hydroxytamoxifen treatment, a few small adenomas are observed in some animals
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Edil3Tg(Sox2-cre)1Amc mutation
(5 available);
any
Edil3 mutation
(42 available)
Mapk14tm2Nbr mutation
(2 available);
any
Mapk14 mutation
(41 available)
Mapk14tm3.1(Mapk11)Nbr mutation
(0 available);
any
Mapk14 mutation
(41 available)
|
|
|
mortality/aging
|
|
• about 30% of mice survive to adulthood
|
Analysis Tools